H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences to $17 from $19 and keeps a Buy rating on the shares. The company announced that its ongoing Phase 3 PEAK trial, which is evaluating bezuclastinib in combination with sunitinib for the treatment of patients with gastrointestinal stromal tumors, completed enrollment of 413 patients, the analyst tells investors in a research note. The firm cites the increased share count for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences announces trials in patients with GIST completes enrollment
- Cogent Biosciences price target lowered to $20 from $26 at Guggenheim
- Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
- Cogent Biosciences expects cash to fund operations into 2027
- Cogent Biosciences announces upcoming milestones